FDA DEVICE FACTS
EchoGo Pro
Ultromics, Ltd.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
EchoGo Pro v1.0.2 is a machine lear ning-based decision support system, indicated as an adjunct to diagnostic stress echo cardiography for patients undergoing assessment for coronary artery disease (CAD). When utilized by an interpreting physician, this device provides information that may be useful in rendering an accurate diagnosis . Patient management decisions should not be made solely on the results of the EchoGo Pro v1.0.2 analysis. Ec hoGo Pro v1.0.2 is to be used with stress echo exam protocols th at contain A2C, A4C and mid-ventricular short-axis views at rest and at peak stress. EchoGo Pro vl.0.2 is not intended for the assessment of mild or moderate myocardial ischemia, or localization of corona ry artery disease, or for the assessment of myocardial perfusion, myocardial viability or valve disease. Limitations: EchoGo Pro v1.0.2 has not been validated on patients who underwent previous coronary artery bypass graft (CABG) surgery.”
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。